Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...
This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.
From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...
CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback